-
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
•
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the…
-
Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China
•
GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from the National Medical Products Administration (NMPA) to proceed with clinical studies for BAT2406, a biosimilar version of Sanofi’s Dupixent (dupilumab). This monoclonal antibody, which targets interleukin-4 (IL-4) and interleukin-13 (IL-13), is now set to be…
-
NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation
•
The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of reference drugs for its Generic Quality Consistency Evaluation (GQCE) program. This latest batch includes 25 new specifications and modifications to 8 existing ones, featuring a drug with a newly changed generic name, enarodustat, along with…
-
Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion
•
HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan for High Quality Development of Digital Health System and Digital Health Economy (2024-2026),” setting its sights on establishing a comprehensive, industry-leading digital health ecosystem. The plan envisions a vibrant innovation landscape that benefits the public,…
-
China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions
•
BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production and Construction Corps (Bingtuan) have incorporated assisted reproductive technology (ART) into their medical insurance reimbursement schemes. This move marks a significant expansion in healthcare coverage, with regions such as Beijing, Guangxi, Inner Mongolia, Gansu, and…
-
BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman
•
NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment of Jean-Pierre Garnier, the former chief executive officer of GlaxoSmithKline (GSK, NYSE: GSK), as Chairman of its board of directors. Garnier’s extensive experience in the pharmaceutical industry is expected to provide strategic guidance as BioAge…
-
China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns
•
BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import, sales, and use of Dr. Reddy’s Laboratories Ltd.’s atomoxetine hydrochloride capsules in China. The decision comes after the Indian pharmaceutical company’s product, which won a bid in the 9th round of China’s volume-based procurement (VBP),…
-
Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion
•
SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the Suzhou Industrial Park, marking a significant expansion of its presence in China. The company will invest RMB 3 billion in a new project for its Suzhou plant, which is anticipated to be operational by 2028.…
